×

Biomarkers

Refining management of lung cancer: ctDNA testing comes of age

Refining management of lung cancer: ctDNA testing comes of age

Lung cancer is the leading cause of cancer death, accounting for 18.4% of the total cancer deaths worldwide. Despite major advances in cancer care, lung cancer is associated with a high mortality rate, in part because of late-stage diagnosis, for which the 5-year survival rate is approximately 4%.

read more
SCLC has metabolically different, targetable subtypes

SCLC has metabolically different, targetable subtypes

A diagnosis of small-cell lung cancer (SCLC) carries with it a grim prognosis. Standard therapy for extensive-stage disease, which consists of combination chemotherapy and radiation, is associated with 5-year overall survival rates of just 5%-10%.

read more
B7-H3 stands out as future SCLC target

B7-H3 stands out as future SCLC target

BY CHRISTINE KILGORE MDedge News FROM THE JOURNAL FOR IMMUNOTHERAPY OF CANCER About two out of three patients with small cell lung cancer (SCLC) express B7-H3, a B7 family ligand that may one day serve as a therapeutic target, according to investigators....

read more

Continue Reading


Biomarkers


+

Prevention


+

Cost And Coping


+

Diagnosis and Therapy


+

Patient Journey


+